RMD

Business profile & competitive position

ResMed Inc. operates in the Healthcare sector, specifically the Medical - Instruments & Supplies industry. The company is a global developer of digital health and cloud-connected medical devices for sleep and breathing health, including CPAP, APAP, bilevel, and ventilation devices, plus masks, diagnostics, dental devices, and connected-care software. It also sells cloud-based Residential Care Software to home medical equipment, home health, hospice, skilled nursing, and senior living providers, and distributes products through subsidiaries and independent distributors in more than 140 countries.

The financial profile supports the idea of a durable business model. ResMed’s net margin of 26.9% and return on equity of 23.9% are well above what most capital-intensive hardware or commodity suppliers deliver, suggesting the company extracts real pricing power from recurring mask and accessory revenue, a global installed base, and its digital ecosystem. Healthcare device companies do not typically earn those kinds of returns unless customers face switching costs and the product mix carries repeat-purchase components, such as masks that need replacement every few months. That said, the moat is not absolute: competitors in the sleep-disordered-breathing and respiratory-care markets still fight for device share, and reimbursement decisions by public and private payers can compress economics quickly.

Financial posture

ResMed currently carries a market capitalization of $33.7 billion and trades at a price-to-earnings ratio of 22.9. That P/E sits below the multiples often awarded to fast-growing software companies but above the valuations typical of slow-growing medical distributors, which is consistent with a business that mixes hardware, recurring consumables, and software subscriptions. A net margin of 26.9% and ROE of 23.9% confirm that the company converts revenue into shareholder returns efficiently. The beta of 0.75 indicates the stock has historically been less volatile than the overall market, a common feature of large-cap healthcare companies with recurring revenue streams and defensive demand drivers.

Those figures do not make the stock cheap or expensive on their own; they simply frame ResMed as a high-quality, profitable, relatively low-beta medical-device business. Investors assessing the name would weigh the 22.9 P/E against expected revenue growth, margin sustainability, and how much of the future is already priced in.

Strategic priorities & outlook

ResMed’s most recent 10-K filing outlines a strategy built around deepening its core sleep-apnea franchise while expanding into adjacent breathing and sleep-health conditions. The company plans to grow and differentiate its sleep-apnea portfolio by integrating artificial intelligence and machine learning, simplifying care pathways, and expanding home diagnostics. Recent examples include the NightOwl platform and the VirtuOx IDTF acquisition, both aimed at moving diagnostics out of clinics and into the home.

Management also wants to accelerate market growth by driving awareness and education among patients, physicians, and special-interest groups for sleep apnea, COPD, and related comorbidities. Adjacent opportunities include COPD, neuromuscular disease, and restless legs syndrome, with the Noctrix acquisition supporting the latter. A parallel priority is investment in an integrated, intelligent digital-health ecosystem delivered at home, anchored by AirView remote monitoring and the myAir patient engagement platform.

Operationally, ResMed reports two segments. In fiscal 2026, devices generated roughly 51% of net revenue, masks, diagnostics, and accessories contributed approximately 37%, and software made up about 12%. The company also said in June 2026 that it agreed to sell its MatrixCare business for $490 million in cash to sharpen focus on core sleep, breathing, and connected home-based healthcare; the transaction is expected to close in the first quarter of fiscal 2027. As of the filing, ResMed employed approximately 11,370 people, had more than 35 million cloud-connected devices on AirView, and over 12 million patients registered on myAir.

Macro & geopolitical exposure

Because ResMed sits in the Medical - Instruments & Supplies industry, its macro exposures are those common to medical-device manufacturers rather than, say, biotechnology or pharmaceutical companies. The most persistent risk is reimbursement pressure: public programs such as Medicare and Medicaid, along with private insurers, set coverage and payment rates for devices and related services, and any reduction in allowable reimbursement can ripple through demand and pricing.

Regulatory clearance and post-market surveillance are also defining risks. Products sold in the United States need Food and Drug Administration oversight, and foreign markets carry their own approval and quality regimes, so changes in enforcement or standards can affect launches and product lines. Supply-chain exposure matters as well: CPAP and ventilator devices rely on semiconductors, electronic components, and specialized resins for masks, so trade policy, tariffs, logistics disruptions, or commodity price shifts can influence margins. With sales in more than 140 countries, currency translation adds another variable, as a stronger U.S. dollar can reduce the value of overseas revenue reported in dollars.

Recent developments

The most recent news flow is anchored by product launches, insider transactions, and the upcoming earnings calendar. On October 19, 2026, ResMed announced the U.S. launch of the AirTouch™ F40 full-face fabric CPAP mask, an effort to refresh the mask portfolio that supports the higher-margin recurring-revenue stream. On October 11, 2026, Seeking Alpha included ResMed in its “Top 50 High-Quality Dividend Growth Stocks For October 2026,” and the same day a filing disclosed that ResMed’s CEO sold $1,129,613.03 in stock. Insider sales can reflect personal liquidity decisions rather than a management view on valuation, but the size and timing are worth noting alongside the earnings calendar.

On October 1, 2026, ResMed said it would report first quarter fiscal 2027 earnings on October 29, 2026, after the market closes. With the stock at $239.405 and RSI at 66.8 as of the latest snapshot, the shares are coming into the report with some near-term momentum relative to the 50-day EMA of $225.15.

Earnings behavior & post-earnings drift

ResMed has a strong recent earnings record. Over the last eight reported quarters, the company beat analyst estimates seven times, for an 88% beat rate, with an average earnings surprise of 3%. Despite the beats, the post-earnings price reaction has been restrained: the average 5-day price move after earnings across those quarters is just 0.24%, classified as flat.

The last four reports illustrate the pattern clearly. On August 6, 2026, ResMed reported EPS of $2.95 against an estimate of $2.89, a 2.1% beat, yet the stock fell 5.06% the next day and only recovered to a 1.57% gain over the following five sessions. On April 30, 2026, EPS of $2.86 beat the $2.80 estimate by 2.1%, but the stock dropped 4.11% the next day and was down 3.24% after five days. The January 29, 2026 quarter was the exception to the negative next-day reaction: EPS of $2.81 beat a $2.74 estimate by 2.6%, the stock rose 0.27% the next day, and it gained 3.66% over the following five days. On October 30, 2025, EPS of $2.55 beat a $2.51 estimate by 1.6%, yet the stock declined 2.13% the next day and was down 1.03% over five days.

That history suggests that simply beating consensus has not been enough to drive sustained post-earnings upside. With fiscal Q1 2027 earnings scheduled for October 29, 2026 after the close and the current consensus EPS estimate at $2.68, traders will likely focus on guidance, margin trajectory, and commentary on the MatrixCare sale close as well as the top-line trend.

For readers who want to go further than these headline numbers, the full institutional verdict—covering consensus estimate revisions, analyst rating shifts, and forward margin assumptions—offers the deeper dive needed to put ResMed’s valuation and earnings setup into full context.